Fundraising Fox
/Companies
Sign in

Orisdx

Chicago, US · Founded 2022 · Delaware corporation · 9 employees on LinkedIn · 2 known investors

Find your way into Orisdx

Sign up to see every warm intro you have to Orisdx

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Orisdx team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

OrisDX develops a non-invasive salivary-rinse DNA test called Oro Lesion to detect early markers of oral cavity squamous cell carcinoma in adults with indeterminate oral lesions. It pairs the test with Oris Bridge, a digital health patient navigator that handles clinical referrals, patient education, and medical claim automation and review.

BiotechDigital HealthMedical Devices

Founders & leadership

HSHarald Steltzer
Harald SteltzerChief Executive OfficerHarald Steltzer has spent over three decades in life sciences and healthcare entrepreneurship, with expertise in business strategy, market access, and corporate development across the healthcare industry.
PCPatrick Conniff
Patrick ConniffChief Operating & Financial OfficerHe previously worked across life sciences, consumer products, and nonprofit sectors on fundraising, partnerships, and business development, and earned his MBA from Booth School of Business.
EI
Evgeny IzmchenkoNamed on SEC filing
NANishant Agrawal
Nishant AgrawalCo-Founder

Investors · 2

HARPER COURT VENTURESlisted by HARPER COURT VENTURESChicagovia Karthee Madasamy · inferred

How we know: HARPER COURT VENTURES's portfolio page · Not right? Tell us

Reported raises · per SEC filings

Form D private placements

$2.8M disclosed across 1 round · 2025

▶$2.8MraisedJul 2025 · 25 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Harald SteltzerExecutive Officer, Director
  • Evgeny IzmchenkoDirector
  • Patrick ConniffExecutive Officer
  • Nishant AgrawalDirector
Offering amount
$4M
Amount sold
$2.8M
First sale
May 2025
Incorporated
Corporation, Delaware, 2022
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Frequently asked questions

What does Orisdx do?
OrisDX develops a non-invasive salivary-rinse DNA test called Oro Lesion to detect early markers of oral cavity squamous cell carcinoma in adults with indeterminate oral lesions. It pairs the test with Oris Bridge, a digital health patient navigator that handles clinical referrals, patient education, and medical claim automation and review.
Who are Orisdx's investors?
Orisdx's investors include Angel Physicians Fund, HARPER COURT VENTURES.
How much funding has Orisdx raised?
Orisdx has disclosed $2.8M raised across 1 round.
Where is Orisdx headquartered?
Orisdx is headquartered in Chicago, US.